Cardiol Therapeutics Inc.

Cardiol's President/CEO David Elsley sat down with Stocks to Watch to discuss our approach to targeting inflammation in heart disease — and what's ahead for $CRDL. 🎥 Watch the full interview: youtube.com/watch?v=NXkzgf… #HeartDisease #Biotech #CRDL #Pericarditis #Inflammation

REPLAY: President/CEO David Elsley & CMO/Head of R&D Andrew Hamer joined @HCWCO yesterday in a Fireside Chat hosted by Brandon Folkes to discuss the pivotal Phase III MAVERIC trial, key value-driving milestones, and development of CRD-38. 🔗 Watch here: journey.ct.events/view/8d043006-…

REMINDER: Cardiol Therapeutics will be presenting a Fireside Chat today at 1:30 p.m. ET at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq in New York City. $CRDL 📺Watch our Fireside Chat live via webcast — register here: journey.ct.events/view/8d043006-…

We're pleased to share that Cardiol Therapeutics will participate in a Fireside Chat at the @HCWCO 4th Annual BioConnect Investor Conference, hosted at the @Nasdaq in New York City. Tune in on May 19 at 1:30 p.m. ET via live webcast. A replay will be available for 90 days. $CRDL cardiolrx.com/cardiol-therap…

We’re proud to support @PericarditisA 1st Annual Platypus Run on May 16, 2026! The event helps raise awareness of pericarditis and brings together patients, families, and supporters through a 5K run, 1-mile walk, and virtual participation option. We’re pleased to stand with The Pericarditis Alliance in support of education, awareness, and patients living with this condition.

Very informative paper from the great team of our MAVERIC trial collaborators at the @ClevelandClinic!

These results support our ongoing Phase III MAVERIC trial, evaluating CardiolRx™ for the prevention of recurrent pericarditis. Enrollment has surpassed 75%, with full enrollment anticipated in the next few months. We’ll share the link to the full publication once it is available.

The peer-reviewed findings demonstrate rapid and sustained reductions in pericarditis pain and inflammation, a substantial reduction in pericarditis episodes per year, and a favorable safety profile in patients with high baseline disease burden.

Today we announced the results from our Phase II MAvERIC study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association (@JAHA_AHA). #JAHA #ClinicalTrials #CardiolRx $CRDL cardiolrx.com/cardiol-therap…

HFpEF now accounts for >50% of all heart failure cases — and most existing therapies were built for a different disease. It will affect nearly one in 10 people by the age of 45. In Canada, it is one of the leading causes of hospitalization for people over 65. The answer lies upstream — before structural damage becomes visible. #HFpEF #HeartFailureWeek cardiolrx.com/why-the-most-c…

This week is Heart Failure Awareness Week in Canada. Over 850,000 Canadians are living with heart failure, with more than 100,000 new diagnoses expected this year. 1-in-4 people will develop HF in their lifetime. At Cardiol, we’re advancing anti-inflammatory and anti-fibrotic therapies with the potential to change outcomes for patients with heart failure and other inflammatory heart diseases. Learn more about HF Awareness Week and access important resources 👉 heartfailure.ca/heart-failure-… @CanHFSociety #HeartFailureWeekCan $CRDL

From rare disease to heart failure. David Elsley highlights how ARCHER findings may open new directions across inflammatory heart disease, including rare disease and large-market indications. $CRDL

“Broadening the MAVERIC clinical site network reflects the strong interest we have received from leading clinical centers across the United States and underscores the level of investigator conviction in both the therapeutic rationale and the unmet need in recurrent pericarditis,” said David Elsley, President and Chief Executive Officer. $CRDL

We’re pleased to announce the expansion of the U.S. MAVERIC Phase III trial network to address growing interest in the pivotal program. Patient enrollment surpassed 50% in early January and has now reached 75%. $CRDL 🔗Read more: cardiolrx.com/cardiol-therap…

Persistent inflammation can lead to irreversible damage in the heart. David Elsley highlights Cardiol’s cardioprotective approach, designed to reduce inflammation-driven structural damage in the heart and support recovery. $CRDL

Cardiol Therapeutics’ President/CEO David Elsley joined @EllisMartinRprt to discuss clinical progress and the Company’s approach to targeting inflammation in heart disease. Topics include ARCHER data, MAVERIC trial progress, and CRD-38. $CRDL 🔗 Listen here: youtu.be/UEP3jaMZIcY

A better understanding of heart failure is opening new opportunities. David Elsley highlights why targeting inflammation, without suppressing the immune system, sits at the center of Cardiol’s approach. $CRDL

More than 64 million people worldwide are living with heart failure. In the United States, that number is projected to grow from 6.7 million today to more than 11 million by 2050. In Canada, 750,000 people are living with the condition and more than 90,000 are newly diagnosed every year. One in four people will develop heart failure in their lifetime. With National Heart Failure Awareness Week approaching we took a closer look at what the data shows and what it means. $CRDL #HFWeek2026 #HFpEF cardiolrx.com/heart-failure-…

MAVERIC is designed as a pivotal Phase III study to support a potential NDA. President/CEO David Elsley highlights alignment with the FDA on the study’s primary endpoint. $CRDL

A non-immunosuppressive approach to treating inflammatory heart disease. President/CEO David Elsley highlights how Cardiol’s therapies are designed to modulate inflammation while preserving immune function, with potential for both acute and long-term use. $CRDL